Overview

Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor AntagonistDiphenhydraminein Advanced and Metastatic Non-Small Cell Lung Cancer

Status:
NOT_YET_RECRUITING

Trial end date:
2027-11-01

Target enrollment:

Participant gender:

Summary

The goal of this clinical trial is to learn if diphenhydramine can improve the effectiveness and decrease the toxicity for the treatment of advanced and metastatic Non-small cell lung cancer (NSCLC) with PD1 inhibitor plus chemotherapy. The main questions it aims to answer are: * Dose diphenhydramine improve the effectiveness and survival of advanced and metastatic NSCLC treated with PD1 inhibitor and chemotherapy? * Dose diphenhydramine decrease the toxicity of PD1 inhibitor plus platinum-based chemotherapy? * Researchers will compare patients with or without diphenhydramine to see if diphenhydramine works to improve the effectiveness and decrease the toxicity. Participants will: * Take standard treatment (tislelizumab and platinum-based chemotherapy) with/without diphenhydramine20mg qd d0-2every cycle. * Visit the clinic once every six weeks for checkups and tests * Keep a diary of their symptoms and survival visit based on the protocol.

Phase:

PHASE3

Details

Lead Sponsor:

Tianjin Medical University Cancer Institute and Hospital

Treatments:

Carboplatin
Cisplatin
Diphenhydramine
Pemetrexed
tislelizumab